Objective:

To compare treatment failure rates and adverse events between standard-dose amoxicillin-clavulanate and standard-dose amoxicillin in adults aged 18 to 64 years with uncomplicated acute sinusitis.

Key Findings:

• Treatment failure rates were similar (about 3%) for both amoxicillin-clavulanate and amoxicillin, indicating comparable effectiveness.
• Secondary infections occurred more frequently with amoxicillin-clavulanate (1.2% vs 0.8%), suggesting a potential risk factor.
• Antibiotic-associated adverse events were similar between groups (about 1% each), indicating safety profiles are comparable.
• Gastrointestinal symptoms were the most common adverse events, highlighting a need for monitoring.
• No meaningful differences were observed across age groups, sex, immune status, or dosing strategies, reinforcing the generalizability of the findings.

Interpretation:

Standard-dose amoxicillin is supported as a preferred first-line treatment for uncomplicated acute sinusitis, particularly in patients without recent antibiotic exposure, emphasizing its clinical relevance.

Limitations:

• Observational design with potential residual confounding, which may affect the validity of the results.
• Lack of adherence data and microbiologic confirmation, limiting the robustness of the conclusions.
• Study limited to commercially insured patients, which may not represent the broader population.
• Over-the-counter medication use and socioeconomic data were not captured, potentially influencing outcomes.

Conclusion:

The findings suggest that amoxicillin is as effective as amoxicillin-clavulanate for treating uncomplicated acute sinusitis, with a lower risk of secondary infections, underscoring its role in treatment guidelines.

Sources:

• JAMA